Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Seidman

Showing results (341-350 of 386) with videos related to

Pageof 39
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2008
Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840Andrew D Seidman, Donald Berry, Constance Cirrincione, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 17, 2011
A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancerM N Fornier, P G Morris, A Abbruzzi, et al.
Clinical Breast Cancer|May 19, 2005
A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxaneShanu Modi, Violante E Currie, Andrew D Seidman, et al.
Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery|June 17, 2011
Clinical practice guideline: Polysomnography for sleep-disordered breathing prior to tonsillectomy in childrenPeter S Roland, Richard M Rosenfeld, Lee J Brooks, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 1999
Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancerG D'Andrea, D Fennelly, L Norton, et al.
Advances in Radiation Oncology|March 17, 2025
Local Therapy for Isolated Central Nervous System Progression Among Patients Receiving Antibody-Drug Conjugate TherapyEmily S Lebow, Jordan Eichholz, Zhigang Zhang, et al.
Seminars in Oncology|September 11, 1999
Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancerJ Baselga, D Tripathy, J Mendelsohn, et al.
Neuro-Oncology|July 13, 2014
Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective studyAki Morikawa, David M Peereboom, Helen R Thorsheim, et al.
European Journal of Cancer (Oxford, England : 1990)|July 16, 2018
A phase IIA trial of acupuncture to reduce chemotherapy-induced peripheral neuropathy severity during neoadjuvant or adjuvant weekly paclitaxel chemotherapy in breast cancer patientsTing Bao, Andrew D Seidman, Lauren Piulson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1996
Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancerJ Baselga, D Tripathy, J Mendelsohn, et al.
Pageof 39

Showing results (341-350 of 386) with videos related to

Sort By:
Pageof 39
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2008
Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840Andrew D Seidman, Donald Berry, Constance Cirrincione, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 17, 2011
A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancerM N Fornier, P G Morris, A Abbruzzi, et al.
Clinical Breast Cancer|May 19, 2005
A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxaneShanu Modi, Violante E Currie, Andrew D Seidman, et al.
Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery|June 17, 2011
Clinical practice guideline: Polysomnography for sleep-disordered breathing prior to tonsillectomy in childrenPeter S Roland, Richard M Rosenfeld, Lee J Brooks, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 1999
Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancerG D'Andrea, D Fennelly, L Norton, et al.
Advances in Radiation Oncology|March 17, 2025
Local Therapy for Isolated Central Nervous System Progression Among Patients Receiving Antibody-Drug Conjugate TherapyEmily S Lebow, Jordan Eichholz, Zhigang Zhang, et al.
Seminars in Oncology|September 11, 1999
Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancerJ Baselga, D Tripathy, J Mendelsohn, et al.
Neuro-Oncology|July 13, 2014
Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective studyAki Morikawa, David M Peereboom, Helen R Thorsheim, et al.
European Journal of Cancer (Oxford, England : 1990)|July 16, 2018
A phase IIA trial of acupuncture to reduce chemotherapy-induced peripheral neuropathy severity during neoadjuvant or adjuvant weekly paclitaxel chemotherapy in breast cancer patientsTing Bao, Andrew D Seidman, Lauren Piulson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1996
Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancerJ Baselga, D Tripathy, J Mendelsohn, et al.
Pageof 39